Neurocrine Biosciences Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Neurocrine Biosciences Inc trades at $141.27 (market cap $14.36B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.28 (market cap $28.69M). The key difference: Neurocrine Biosciences Inc is far larger — about 500.5× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is more actively traded (22,490 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 60 Days on average.
| NBIX | QDTY | |
|---|---|---|
Market Cap | $14.36B | $28.69M |
Volume | 1,237,180 | 22,490 |
Sector | Health | Income / Options Overlay |
52-Week High | $185.50 | $46.71 |
52-Week Low | $123.10 | $36.57 |
Typical Hold Time | 23 Days | 60 Days |
Enterprise Value | $14.37B | — |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →